The Meals and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, however with notable limitations.
Beforehand obtainable underneath emergency use authorization for people aged 12 and up, the shot is now totally permitted just for adults 65 and older, or for these between the ages of 12 and 64 who’ve underlying well being circumstances that heighten their danger of extreme COVID-19.
The outlook for the vaccine grew to become unsure after the FDA failed to fulfill its April 1 approval deadline. Including to the uncertainty, U.S. Well being and Human Companies Secretary Robert F. Kennedy Jr., identified for his skepticism towards vaccines, questioned the shot’s effectiveness throughout an interview with CBS.
Novavax, Inc. (NASDAQ:NVAX)’s vaccine stands out as the one protein-based COVID-19 shot obtainable within the U.S., providing a substitute for the mRNA-based vaccines from Pfizer and Moderna. Each of these vaccines have already got full FDA approval for people 12 and older, and are licensed to be used in kids as younger as 6 months.
The information got here after Novavax, Inc. (NASDAQ:NVAX) recorded robust earnings within the first quarter of 2025. The corporate posted income of $666.6 million, which confirmed a major development of 610.3% from the identical interval final 12 months. The income additionally beat analysts’ estimates by $322.8 million. Its EPS of $2.93 additionally surpassed the estimates by $1.52. The corporate additionally enhanced its partnership with Takeda in Japan, which is ranked because the world’s third-largest pharmaceutical market, bringing notably higher monetary phrases.
Whereas we acknowledge the potential of NVAX to develop, our conviction lies within the perception that some AI shares maintain larger promise for delivering increased returns and have restricted draw back danger. If you’re on the lookout for an AI inventory that’s extra promising than NVAX and that has 100x upside potential, try our report about this least expensive AI inventory.
READ NEXT: 12 Greatest Mid-Cap Dividend Aristocrats to Put money into Now and Dividend Challengers 2025: High 25
Disclosure. None.